ANI Pharmaceuticals, Inc. — FY 2016 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2016. ANI is a U.S.-focused specialty pharmaceutical company that develops, acquires, manufactures, and markets branded and generic prescription drugs, emphasizing complex and niche products. It operates two manufacturing facilities in Baudette, Minnesota and reports one business segment.
Financial performance
| Metric | FY 2016 | FY 2015 | Change |
|---|---|---|---|
| Net revenue | $128.6 million | $76.3 million | +68.5% |
| Operating income | $20.1 million | $32.7 million | Down $12.6 million |
| Operating margin | 15.6% | 42.8% | Down 27.2 percentage points |
| Net income | $3.9 million | $15.4 million | Down $11.4 million |
| Diluted EPS | $0.34 | $1.32 | Down $0.98 |
| Cash from operations | $27.5 million | $17.3 million | Up $10.2 million |
- Revenue growth reflected new product launches and acquired product rights. Generic product revenue rose 72.6% to $95.2 million; branded product revenue rose 140.3% to $26.4 million.
- Cost of sales, excluding depreciation and amortization, increased to $48.8 million from $12.7 million. It equaled 37.9% of revenue versus 16.6% in 2015; management cited profit-sharing products and $5.9 million of acquired Inderal LA/Propranolol ER inventory fair-value step-up sold during the year.
- Depreciation and amortization increased to $22.3 million from $6.9 million, primarily following acquisitions. The company also recorded a $6.7 million impairment on its testosterone gel NDA.
- Net interest expense was $11.3 million. The reported effective income tax rate was 54.7%, driven in part by the international tax structure surrounding the Corticotropin acquisitions.
- Cash and equivalents were $27.4 million at year-end, versus $154.7 million a year earlier; an additional $5.0 million was restricted in escrow. Current assets were $103.0 million and current liabilities $31.9 million; management reported a 3.2 working-capital ratio.
- Investing activities used $154.1 million, principally for the Corticotropin/Corticotropin-Zinc, Inderal LA, and H2-Pharma rights acquisitions. Financing activities used $0.7 million. Capital expenditures were $4.6 million.
- At year-end, convertible notes had $143.75 million principal and a $120.6 million net carrying value; they bear a 3.0% coupon and mature in December 2019. No amount was drawn on the $30 million asset-based revolving facility at December 31, 2016.
Material changes and unusual items
- ANI launched 11 products in 2016, bringing its portfolio to 25. Significant launches included Inderal LA and Propranolol ER, Fenofibrate, hydrocortisone rectal cream, Nilutamide, and Erythromycin Ethylsuccinate.
- Acquisitions included Corticotropin and Corticotropin-Zinc for $75.0 million, Inderal LA for $60.0 million upfront plus milestones, and H2-Pharma marketing and distribution rights for $10.0 million total consideration.
- Fourth-quarter revenue was $38.2 million, operating income $1.3 million, and net loss $1.1 million. The filing reports the testosterone-gel impairment for FY 2016 but does not clearly quantify its specific effect on fourth-quarter results.
- Contract services and other income declined 72.6% to $1.4 million, primarily because ANI no longer received royalties on the prior Vancocin authorized generic arrangement.
- After year-end, ANI completed two acquisitions: Inderal XL for $20.2 million cash and InnoPran XL for $30.6 million. It drew $30.0 million on its credit facility to fund the latter and increased the facility commitment to $40.0 million.
Outlook, risks, and contingencies
- Management anticipated higher 2017 revenue from a full year of 2016 launches and additional planned launches. It also expected cost of sales, R&D, SG&A, and amortization to increase. No numerical revenue or earnings guidance was provided.
- Two products marketed without FDA-approved NDAs or ANDAs—EEMT and Opium Tincture—represented 27% of 2016 revenue ($34.3 million). EEMT alone represented 23% of revenue and relies entirely on imported API. FDA action, supply interruptions, or additional competition could materially affect results.
- Revenue and receivables are concentrated: three wholesalers accounted for 68% of 2016 revenue, and those customers represented approximately 83% of year-end net receivables. EEMT, Inderal LA, and Propranolol ER together contributed approximately 44% of revenue.
- ANI depends on limited or single-source API suppliers and requires annual DEA quotas for controlled-substance ingredients. Regulatory, quality, manufacturing, pricing, rebate, and reimbursement changes pose additional risks. Accruals for chargebacks, rebates, returns, and other allowances exceed 50% of gross branded and generic product sales.
- The FDA disputed ANI’s CBE-30 filing related to Erythromycin Ethylsuccinate and later stated a Prior Approval Supplement was required. ANI continued marketing the product, filed a PAS that was accepted, and reported an FDA action date of June 2017.
- ANI disclosed an unresolved Louisiana Medicaid lawsuit seeking unspecified damages and penalties, and remaining metoclopramide litigation in states other than California and New Jersey. The California cases were settled in 2016; the insurer paid those settlement losses. ANI stated it could not assess the likely outcome of remaining cases.
- Management said available resources and anticipated operating revenue were expected to cover working-capital needs for at least 12 months. This outlook is subject to operating assumptions and acquisition-related cash requirements. The independent auditor gave unqualified opinions on the financial statements and internal controls.
Key facts investors should verify
- Whether new products and acquisitions produce sustainable revenue and margins, given the sharp decline in operating and net margins in 2016.
- The regulatory and commercial status of EEMT, Opium Tincture, and the Erythromycin Ethylsuccinate filing dispute; confirm any FDA decisions after the stated June 2017 action date.
- Post-acquisition liquidity, borrowing, and debt-service capacity after the two February 2017 acquisitions and $30 million credit draw.
- Revenue and receivables concentration among major wholesalers, plus the adequacy of rebate, chargeback, and returns accruals.
- Progress and commercialization costs for Corticotropin and Corticotropin-Zinc, and the outcome of efforts to sell the impaired testosterone gel NDA.